SCHEMBL167713

SCHEMBL167713

NC(=O)Nc1cccc(F)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
RAB9A P51151 2/20 0.61
TSHR P16473 2/20 0.61
HPGD P15428 2/20 0.61
NPC1 O15118 1/20 0.61
ALDH1A1 P00352 2/20 0.59
IDO1 P14902 1/20 0.58
MAPK10 P53779 1/20 0.56
KCNH2 Q12809 1/20 0.56
MAPT P10636 1/20 0.55
THRB P10828 1/20 0.55
HTT P42858 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
GAA P10253 1/20 0.54
MTOR P42345 1/20 0.54
TAAR1 Q96RJ0 1/20 0.54
KCNK3 O14649 1/20 0.53
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL27899663 0.93 MEN1 (0.59) MEN1KMT2ARAB9ATSHRHPGD
Malonic Acid SCHEMBL27899662 0.91 MEN1 (0.62) MEN1KMT2ARAB9ATSHRHPGD
SCHEMBL27899660 0.91 KMT2A (0.57) MEN1KMT2ARAB9ATSHRHPGD
Nitric Acid SCHEMBL3442027 0.90 MEN1 (0.56) MEN1KMT2ARAB9ATSHRHPGD
Maleic Acid SCHEMBL27899766 0.90 MMP1 (0.56) MEN1KMT2ARAB9ATSHRHPGD
Trifluoroacetic Acid SCHEMBL6506840 0.90 CHIT1 (0.57) MEN1KMT2ARAB9ATSHRHPGD
Cadaverine Tartrate SCHEMBL27917346 0.88 MEN1 (0.54) MEN1KMT2ARAB9ATSHRHPGD
SCHEMBL3690365 0.85 MAPT (0.59) MEN1KMT2ANPC1ALDH1A1MAPT
SCHEMBL13906101 0.85 MEN1 (0.62) MEN1KMT2ARAB9ATSHRHPGD
SCHEMBL30851500 0.83 RAB9A (0.79) MEN1KMT2ARAB9ATSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025122121-A2 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND THE METHOD OF OBTAINING THESE COMPOUNDS HACETTEPE UNIVERSITESI REKTORLUK (TR) 2025-06-12 WO claimed
US-20240262801-A1 COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES MONDEGO BIO, LDA. (PT) 2024-08-08 US claimed
CN-111526877-B Compounds and compositions for IRE1 inhibition 奥普提卡拉公司 2023-08-25 CN claimed
CN-104902895-B Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases 德西费拉制药有限责任公司 2019-03-29 CN claimed
EP-3119937-B1 METHOD FOR COLOURING CELLULOSE COMMISSARIAT ENERGIE ATOMIQUE (FR) 2018-05-16 EP claimed
US-20170096773-A1 METHOD FOR COLORING CELLULOSE COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2017-04-06 US claimed
EP-3119937-A1 METHOD FOR COLOURING CELLULOSE Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) 2017-01-25 EP claimed
US-9198426-B2 Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-01 US claimed
WO-2015157360-A1 PROCESSES TO MAKE PROTEIN KINASE INHIBITORS ABBVIE INC. (US) 2015-10-15 WO claimed
WO-2015140750-A1 METHOD FOR COLOURING CELLULOSE COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-09-24 WO claimed
CN-101048383-A Gonadotropin releasing hormone receptor antagonists WYETH CORP (US) 2007-10-03 CN claimed
CN-1942475-A Substituted thieno - and thiazolo - [2, 3-d] pyridines as inhibitors of Tie2 ASTRAZENECA AB (SE) 2007-04-04 CN claimed
EP-1737830-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS The Procter and Gamble Company (US) 2007-01-03 EP claimed
WO-2005105757-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2005-11-10 WO claimed
CN-1181070-C Urea substituted imidazoquinolines 3M 2004-12-22 CN claimed
CN-1355701-A Urea substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO (US) 2002-06-26 CN claimed
EP-1124811-A1 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.p.A. (IT) 2001-08-22 EP claimed
WO-2000026203-A1 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2000-05-11 WO claimed
US-5696110-A ANTIULCER AGENTS MERCK, SHARP & DOHME, LTD. (GB) 1997-12-09 US claimed
EP-0652871-A1 BENZODIAZEPINE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1995-05-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262801-A1 COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES PPM1A, TH, PPM1G MEN1 2523/4885KMT2A 1362/4885RAB9A 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.